GlassScriptPhysician profile
Mayona Green
NPI 1306699434
$2,151.96
in general payments reported to CMS, 2019-2025
21 companies · $2,049 in 2025
The $2,049 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $103 · 2025: $2,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $318.47 | 2024-2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $247.41 | 2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $188.87 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $187.24 | 2024-2025 | Rybelsus, Ozempic |
| Mallinckrodt Hospital Products INC. | $164.43 | 2025 | Acthar |
| Astellas Pharma US INC | $157.78 | 2025 | Veozah |
| Dexcom, INC. | $144.86 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbvie INC. | $128.41 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $116.84 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $109.45 | 2025 | |
| Ani Pharmaceuticals, INC. | $80.80 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $61.40 | 2025 | Tarpeyo |
| Scpharmaceuticals INC. | $41.15 | 2025 | |
| Collegium Pharmaceutical, INC. | $39.79 | 2025 | Belbuca |
| Lilly USA, LLC | $34.54 | 2025 | Jardiance, Mounjaro, Zepbound |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $29.40 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $26.47 | 2025 | Capvaxive, Pifeltro |
| Otsuka America Pharmaceutical, INC. | $23.61 | 2025 | Jynarque |
| Kowa Pharmaceuticals America, INC. | $17.95 | 2025 | Zoryve |
| Pfizer INC. | $17.78 | 2025 | |
| Tms Neurohealth Centers INC. | $15.31 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayona Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.